이 애플리케이션의 일부 콘텐츠는 현재 사용할 수 없습니다.
이 상황이 계속되면 다음 주소로 문의하십시오피드백 및 연락
1. (WO2016092546) BINGE BEHAVIOR REGULATORS
유의사항: 이 문서는 자동 광학문자판독장치(OCR)로 처리된 텍스트입니다. 법률상의 용도로 사용하고자 하는 경우 PDF 버전을 사용하십시오

WHAT IS CLAIMED IS:

1. A method of regulating binge behavior, the method comprising administrating to a subject in need thereof a compound represented by Formula I:


Formula I

wherein:

each of Ri and R2 is independently selected from the group consisting of H, ( -C8)alkyl, (C2-C4)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, aryl, heteroaryl, heteroalicyclic, -0(d-C6)alkyl, OH, -OS(=0)2CF3, -OS(=0)2-(Ci-C6)alkyl, -S(=0)R5, -C02R5, -CONR5R6, -COR5, -CF3, CN, -SR5, -SO2NR5R6, -SO2R5, -OCO-(Ci-C6)alkyl, -NCO-(Ci-C6)alkyl, -CH20-(Ci-C6)alkyl, -(Ci-C6)alkyl-OH, and halogen, or, alternatively, Ri and R2 together with two or more of the phenyl carbon atoms form a Xi-(CR5R6)m--X2- ring, wherein each of Xi and X2 is independently selected from O, NH or S and m is 1, 2, 3, or 4;

each of R3 and R4 is independently selected from the group consisting of H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8) cycloalkyl, and -(CH2)p-thienyl, wherein p is 1, 2, 3, or 4, or alternatively, R3 and R4 are joined together to form a heterocylic ring (heteroalicyclic or heteroaryl) containing the nitrogen atom to which they are attached; and

each of R5 and R6 is independently selected from the group consisting of H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C3-C8)cycloalkyl and aryl,

thereby regulating the binge behavior.

2. The method of claim 1, wherein said binge behavior is associated with alcohol consumption, eating, tobacco consumption, shopping or sexual conduct.

3. The method of claim 2, wherein said binge behavior is binge drinking.

4. A method of regulating consumption of an alcoholic beverage, the method comprising administering to a subject in need thereof a compound represented by Formula I, or a composition comprising same:


Formula I

wherein

each of Ri and R2 is independently selected from the group consisting of H, (Q-C8)alkyl, (C2-C4)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, aryl, heteroaryl, heteroalicyclic, -0(Ci-C6)alkyl, OH, -OS(=0)2CF3, -OS(=0)2-(Ci-C6)alkyl, -S(=0)R5, -C02R5, -CONR5R6, -COR5, -CF3, CN, -SR5, -S02NR5R6, -S02R5, -OCO-(Ci-C6)alkyl, -NCO-(Ci-C6)alkyl, -CH20-(Ci-C6)alkyl, -(Ci-C6)alkyl-OH, and halogen, or, alternatively, Ri and R2 together with two or more of the phenyl carbon atoms form a Xi-(CR5R6)m-- 2-ring, wherein each of Xi and X2 is independently selected from O, NH or S and m is 1, 2, 3, or 4;

each of R3 and R4 is independently selected from the group consisting of H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8) cycloalkyl, and -(CH2)p-thienyl, wherein p is 1, 2, 3, or 4, or alternatively, R3 and R4 are joined together to form a heterocylic ring (heteroalicyclic or heteroaryl) containing the nitrogen atom to which they are attached; and

each of R5 and R6 is independently selected from the group consisting of H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C3-C8)cycloalkyl and aryl,

thereby regulating the consumption of an alcoholic beverage.

5. The method of claim 4, wherein said consumption of alcoholic beverage is associated with binge drinking.

6. The method of any one of claims 3 to 5, being for reducing an amount of alcohol consumption during a drinking session.

7. The method of any one of claims 3 to 6, wherein said compound or said composition is administered before, simultaneously with, or subsequent to consumption of an alcoholic beverage.

8. The method of any one of claims 3 to 7, wherein said compound is administered simultaneously with an alcoholic beverage.

9. The method of claim 8, wherein said compound is being incorporated in said alcoholic beverage.

10. The method according to claim 9, wherein the amount of said compound is in the range selected from 0.15 mg/ml to 0.60 mg/ml, 0.15 mg/ml to 0.50 mg/ml, 0.15 to 0.40 mg/ml, 0.18 to 0.50 mg/ml, 0.18 to 0.40 mg/ml, 0.20 to 0.40 mg/ml, 0.20 to 0.30 mg/ml, 0.20 to 0.25 mg/ml, or 0.20 to 0.23 mg/ml.

11. The method of any one of claims 1 to 10, wherein each of Ri and R2, each independently is selected from the group consisting of H, (Ci-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, aryl, -OCH3, OH, -OS02CF3, -OS02CH3, -SORs, -C02R5, -CONR5R6, -COR5, -CF3, -CN, -SR5, -S02NR5R6, -S02R5, -CH2-OH, halogen, phthalimidyl, thiophenyl, pyrrolyl, pyrrolinyl, and oxazolyl, or, alternatively, Ri and R2 together with two or more of the phenyl carbon atoms form a -0(CH2)mO- ring, wherein m is 1 or 2;

R3 and R4 are joined together to form a heterocylic ring containing 4 to 8 carbon atoms with the nitrogen atom to which they are attached; and

Each of R5 and R6 is independently selected from the group consisting of H, (Q-C8) alkyl, (C2-C8) alkenyl, and (C3-C8) cycloalkyl.

The method of any one of claims 1 to 11, wherein at least one of R3 and

13. The method of any one of claims 1 to 11, wherein R3 or R4 is propyl.

14. The method of any one of claims 11 to 13, wherein each of Ri and R2 is independently H, -OCH3, or -OS02CF3, or Ri and R2 together with two or more of the phenyl carbon atom form a -0(CH2)mO- ring, wherein m is 1 or 2.

15. The method of any one of claims 1 to 14, wherein the compound of Formula I is selected from:

5-methoxy-2-aminoindan;

5,6-dimethoxy-2-aminoindan;

5-methoxy-2-(N-propylamino)indan;

5,6-dimethoxy-2-(N-propylamino)indan;

5,6-dimethoxy-2-(di-N-butylamino)indan;

5-(trifluoromethylsulfonyloxy)-2-(N-propylamino)indan;

5,6-(di-trifluoromethylsulfonyloxy)-2-(N-propylamino)Indan;

5,6-dimethoxy-2(pyrrolidino)indan;

5-(trifluoromethylsulfonyloxy)-6-hydroxy-2-(di-N-propylamino)indan;

5-(triluuoromethylsulfonyloxy)-6-acetoxy-2-(di-N-propylarnino)indan;

5-trifluromethansulfonyloxy-6-methoxy-2-(di-N-propylamino)indan;

5,6-ethylenedioxy-2-(di-N-propylamino)indan; and

5,6-methylenedioxy-2-(di-N-propylamino)indan.

16. The method of any one of claims 1 to 15, wherein said compound forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.

17. The method of claim 16, wherein said composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate or a syrup.

18. The method of claim 16 or 17, wherein said composition is a unit dosage form composition.

19. The method of claim 18, wherein an amount of said compound in said unit dosage form ranges from 30 mg to 130 mg.

20. The method of claim 19, wherein said amount of said compound is 70 mg.

21. The method of any one of claims 1 to 20, wherein said compound or composition is administered to a subject orally.

22. A compound represented by Formula I:


Formula I

as defined in any one of claims 1 and 11 to 15, for use in regulating binge behavior.

23. Use of a compound represented by Formula I:


Formula I

as defined in any one of claims 1 and 11 to 15, for the preparation of a medicament for regulating binge behavior.

24. The compound of claim 22, or the use of claim 23, wherein said binge behavior is associated with alcohol consumption, eating, smoking, shopping or sexual conduct.

25. The compound or use of claim 24, wherein said binge behavior is binge drinking.

26. A compound represented by Formula I:


Formula I

as defined in any one of claims 1 and 11 to 15, for use in regulating consumption of an alcoholic beverage.

27. Use of a compound represented by Formula I:


Formula I

as defined in any one of claims 1 and 11 to 15, in the preparation of a medicament for regulating consumption of an alcoholic beverage.

28. The compound of claim 26, or the use of claim 27, wherein said consumption of an alcoholic beverage is associated with binge drinking.

29. The compound or use of any one of claims 22 to 28, wherein said compound is used for reducing an amount of alcohol consumption.

30. The compound or use of claim 29, wherein said compound is for use before, simultaneously with, or subsequently following consumption of an alcoholic beverage.

31. The compound or the use of any one of claims 22 to 30, wherein said compound forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.

32. The compound or the use of claim 31, wherein said composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate or a syrup.

33. The compound or the use of claim 31 or 32, wherein said composition is a unit dosage form composition.

34. The compound or use of claim 33, wherein an amount of said compound in said unit dosage form ranges from 30 mg to 130 mg.

35. The compound or use of claim 34, wherein said amount of said compound is 70 mg.

36. The compound or use of claim 30, wherein said compound or is for use simultaneously with consumption of an alcoholic beverage.

37. The compound or use of claim 36, wherein said compound is being incorporated in said alcoholic beverage.

38. The compound or use according to claim 37, wherein the amount of said compound is in a range selected from 0.15 mg/ml to 0.60 mg/ml, 0.15 mg/ml to 0.50 mg/ml, 0.15 to 0.40 mg/ml, 0.18 to 0.50 mg/ml, 0.18 to 0.40 mg/ml, 0.20 to 0.40 mg/ml, 0.20 to 0.30 mg/ml, 0.20 to 0.25 mg/ml, or 0.20 to 0.23 mg/ml.